Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Highlights:
• Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20, 2022
• The trial will be performed at CMAX Clinical Research, a dedicated and experienced clinical trial centre in Australia, and managed by Avance Clinical
• The trial will assess the pharmacokinetics, safety, and tolerability of combination cannabinoid drug IHL-675A
• Trial data will be applicable to regulatory submissions for all three IHL-675A development programs, rheumatoid arthritis, inflammatory bowel disease and lung inflammation
• Formulation and manufacturing of IHL-675A soft gel capsules for the clinical trial has been completed; long term stability studies are ongoing
• Patient recruitment is scheduled to commence in August 2022.